4月1日 - ** 远程医疗公司Hims & Hers HIMS.N股价上涨11.2%，至32.88美元
** HIMS称其计划 (link)，在其平台上销售礼来LLY.N的减肥和糖尿病药物
** 该公司称，它将同时提供礼来的替齐帕肽（减肥药Zepbound和糖尿病药Mounjaro的活性成分）的品牌版本，以及诺和诺德的NOVOb.CO糖尿病药利拉鲁肽的仿制药。
** HIMS与Teladoc TDOC.N和LifeMD LFMD.O等同行一起，在销售复方药物Zepbound受到限制之前提供礼来的Zepbound。
** 包括本交易日的走势在内，HIMS股价今年以来上涨了36.4%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.